A body of evidence indicates that the altered expression or activity of heparanase determines a profound impact on tumor behavior; indeed, heparin analogs able to inhibit heparanase have been developed to primarily target cancer and some proved very active and have been tested in clinical trials [49]. The gene discussed is HPSE; the disease is cancer.